Form 4: Forte Biosciences Director Reports RSU Grant

Forte Biosciences Director Steven Kornfeld reports the grant of 18,353 Restricted Stock Units (RSUs) vesting on the first annual meeting after May 29, 2026.

Summary

• Steven Kornfeld, a Director at Forte Biosciences, Inc., has reported the acquisition of 18,353 Restricted Stock Units (RSUs).
• These RSUs are subject to vesting conditions, requiring Mr. Kornfeld to remain a Service Provider through the first annual stockholders' meeting occurring after May 29, 2026.
• Upon vesting, each RSU will convert into one share of Forte Biosciences, Inc. Common Stock.
• The transaction was filed on June 2, 2026, with the earliest transaction date noted as May 29, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard RSU grant to a director and does not contain new financial performance data or strategic shifts.

Positives

• Director Steven Kornfeld has been granted a significant number of RSUs, indicating continued commitment and potential future value tied to the company's performance.
• The RSU grant aligns the director's interests with long-term shareholder value, as vesting is tied to continued service and a future annual meeting date.

Risks

• The vesting of the RSUs is contingent upon Mr. Kornfeld's continued service as a Service Provider through the first annual stockholders' meeting after May 29, 2026. Departure before this date would result in forfeiture of the RSUs.
• The value of the RSUs is subject to the future performance and stock price of Forte Biosciences, Inc.

Future Outlook

The future outlook for the RSUs is dependent on the company's performance and Mr. Kornfeld's continued service, with vesting scheduled for the first annual meeting after May 29, 2026.

Industry Context

StockSavvy.ai notes that grants of Restricted Stock Units (RSUs) to directors are a common form of executive compensation in the biotechnology and pharmaceutical sectors, designed to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: The RSU grant represents potential future dilution, but also aligns director incentives with long-term shareholder value.
• Employees: The RSU grant is part of the company's overall compensation strategy, which can impact employee morale and retention.
• Management: The grant reinforces the compensation structure for key personnel.

Next Steps

• Mr. Kornfeld must continue as a Service Provider through the first annual stockholders' meeting after May 29, 2026, for the RSUs to vest.
• The RSUs will convert to common stock upon vesting.

Key Dates

Keywords

Forte Biosciences, FBRX, Form 4, SEC Filing, Restricted Stock Units, RSU, Director, Equity Incentive Plan, Stock Vesting, Beneficial Ownership